These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

140 related articles for article (PubMed ID: 38621153)

  • 1. Telehealth Utilization for Opioid Use Disorder: A Nationwide Analysis Before and After the COVID-19 Public Health Emergency Declaration.
    Lewis KN; Zhang D; Corrales G; Eswaran H; Hayes CJ; Gressler LE
    Telemed J E Health; 2024 Jun; 30(7):e1980-e1989. PubMed ID: 38621153
    [No Abstract]   [Full Text] [Related]  

  • 2. Gender differences in receipt of telehealth versus in person behavioral therapy, medication for opioid use disorder (MOUD), and 90-day MOUD retention during the pandemic: A retrospective veteran cohort study.
    Livingston NA; Sarpong A; Sistad R; Roth C; Banducci AN; Simpson T; Hyde J; Davenport M; Weisberg R
    J Subst Use Addict Treat; 2024 Jan; 156():209188. PubMed ID: 37866437
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Receipt of Telehealth Services, Receipt and Retention of Medications for Opioid Use Disorder, and Medically Treated Overdose Among Medicare Beneficiaries Before and During the COVID-19 Pandemic.
    Jones CM; Shoff C; Hodges K; Blanco C; Losby JL; Ling SM; Compton WM
    JAMA Psychiatry; 2022 Oct; 79(10):981-992. PubMed ID: 36044198
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Telemedicine Use and Quality of Opioid Use Disorder Treatment in the US During the COVID-19 Pandemic.
    Hailu R; Mehrotra A; Huskamp HA; Busch AB; Barnett ML
    JAMA Netw Open; 2023 Jan; 6(1):e2252381. PubMed ID: 36692880
    [TBL] [Abstract][Full Text] [Related]  

  • 5. An examination of telehealth policy impacts on initial rural opioid use disorder treatment patterns during the COVID-19 pandemic.
    Hughes PM; Verrastro G; Fusco CW; Wilson CG; Ostrach B
    J Rural Health; 2021 Jun; 37(3):467-472. PubMed ID: 33720447
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Trends in Opioid Use Disorder Outpatient Treatment and Telehealth Utilization Before and During the COVID-19 Pandemic.
    Tormohlen KN; Eisenberg MD; Fingerhood MI; Yu J; McCourt AD; Stuart EA; Rutkow L; Quintero L; White SA; McGinty EE
    Psychiatr Serv; 2024 Jan; 75(1):72-75. PubMed ID: 37461819
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Telehealth for opioid use disorder treatment in low-barrier clinic settings: an exploration of clinician and staff perspectives.
    Aronowitz SV; Engel-Rebitzer E; Dolan A; Oyekanmi K; Mandell D; Meisel Z; South E; Lowenstein M
    Harm Reduct J; 2021 Nov; 18(1):119. PubMed ID: 34823538
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The COVID-19 pandemic and opioid use disorder: Expanding treatment with buprenorphine, and combining safety precautions with telehealth.
    Cales RH; Cales SC; Shreffler J; Huecker MR
    J Subst Abuse Treat; 2022 Feb; 133():108543. PubMed ID: 34210567
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Trends in Use of Medication to Treat Opioid Use Disorder During the COVID-19 Pandemic in 10 State Medicaid Programs.
    Austin AE; Tang L; Kim JY; Allen L; Barnes AJ; Chang CH; Clark S; Cole ES; Durrance CP; Donohue JM; Gordon AJ; Huskamp HA; McDuffie MJ; Mehrotra A; Mohamoud S; Talbert J; Ahrens KA; Applegate M; Hammerslag LR; Lanier P; Tossone K; Zivin K; Burns ME
    JAMA Health Forum; 2023 Jun; 4(6):e231422. PubMed ID: 37327009
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Utilization and disparities in medication treatment for opioid use disorder among patients with comorbid opioid use disorder and chronic pain during the COVID-19 pandemic.
    Perry A; Wheeler-Martin K; Hasin DS; Terlizzi K; Mannes ZL; Jent V; Townsend TN; Pamplin JR; Crystal S; Martins SS; Cerdá M; Krawczyk N
    Drug Alcohol Depend; 2023 Dec; 253():111023. PubMed ID: 37984034
    [TBL] [Abstract][Full Text] [Related]  

  • 11. How Does Telehealth Expansion Change Access to Healthcare for Patients With Different Types of Substance Use Disorders?
    Tilhou AS; Burns M; Chachlani P; Chen Y; Dague L
    Subst Use Addctn J; 2024 Jul; 45(3):473-485. PubMed ID: 38494728
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Implementing a low-threshold audio-only telehealth model for medication-assisted treatment of opioid use disorder at a community-based non-profit organization in Washington, D.C.
    Yeo EJ; Kralles H; Sternberg D; McCullough D; Nadanasabesan A; Mayo R; Akselrod H; Catalanotti J
    Harm Reduct J; 2021 Dec; 18(1):127. PubMed ID: 34886850
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Assessing the impact of social distancing measures implemented during COVID-19 pandemic on medications for opioid use disorder in West Virginia.
    Haggerty T; Khodaverdi M; Dekeseredy P; Wood N; Hendricks B; Peklinsky J; Sedney CL
    J Subst Abuse Treat; 2022 May; 136():108687. PubMed ID: 34903397
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Impacts of the COVID-19 pandemic on enrollment in medications for opioid use disorder (MOUD) in Vancouver, Canada: An interrupted time series analysis.
    Eugenia Socias M; Choi JC; Fairbairn N; Johnson C; Wilson D; Debeck K; Brar R; Hayashi K
    Int J Drug Policy; 2023 Aug; 118():104075. PubMed ID: 37271070
    [TBL] [Abstract][Full Text] [Related]  

  • 15. COVID-19: A catalyst for change in telehealth service delivery for opioid use disorder management.
    Mehtani NJ; Ristau JT; Snyder H; Surlyn C; Eveland J; Smith-Bernardin S; Knight KR
    Subst Abus; 2021; 42(2):205-212. PubMed ID: 33684331
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Early innovations in opioid use disorder treatment and harm reduction during the COVID-19 pandemic: a scoping review.
    Krawczyk N; Fawole A; Yang J; Tofighi B
    Addict Sci Clin Pract; 2021 Nov; 16(1):68. PubMed ID: 34774106
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Use of Telehealth for Opioid Use Disorder Treatment in Safety Net Primary Care Settings: A Mixed-Methods Study.
    Bailey SR; Wyte-Lake T; Lucas JA; Williams S; Cantone RE; Garvey BT; Hallock-Koppelman L; Angier H; Cohen DJ
    Subst Use Misuse; 2023; 58(9):1143-1151. PubMed ID: 37170596
    [No Abstract]   [Full Text] [Related]  

  • 18. Telehealth in opioid use disorder treatment: policy considerations for expanding access to care.
    Niyibizi A; Haveric A; Irio G
    J Osteopath Med; 2024 Apr; 124(4):179-181. PubMed ID: 37976470
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Primary Care Providers' Experiences Treating Opioid Use Disorder Using Telehealth in the Height of the COVID-19 Pandemic.
    Marshall SA; Siebenmorgen LE; Youngen K; Borders T; Zaller N
    J Prim Care Community Health; 2024; 15():21501319241246359. PubMed ID: 38600789
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Is telemedicine the answer to rural expansion of medication treatment for opioid use disorder? Early experiences in the feasibility study phase of a National Drug Abuse Treatment Clinical Trials Network Trial.
    Hser YI; Ober AJ; Dopp AR; Lin C; Osterhage KP; Clingan SE; Mooney LJ; Curtis ME; Marsch LA; McLeman B; Hichborn E; Lester LS; Baldwin LM; Liu Y; Jacobs P; Saxon AJ
    Addict Sci Clin Pract; 2021 Apr; 16(1):24. PubMed ID: 33879260
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.